Entity

Time filter

Source Type

Paris, France

Nanobiotix is a nanomedicine company dedicated to the development of new treatments for cancer based on the combined application of nanotechnologies and biotechnologies. The company is based in Paris. Wikipedia.


The present application relates to activable inorganic nanoparticles which can be used in the health sector, in particular in human health, to disturb, alter or destroy target cancerous cells, tissues or organs. It more particularly relates to nanoparticles which can generate a surprisingly efficient therapeutic effect, when concentrated inside the tumor and exposed to ionizing radiations. The invention also relates to pharmaceutical compositions comprising a population of nanoparticles as defined previously, as well as to their uses.


Patent
Nanobiotix, French National Center for Scientific Research and University of Bordeaux Segalen | Date: 2015-10-19

The present application relates to a method of monitoring the membrane permeabilization of liposome and the incidental release of a compound of interest.


Patent
Nanobiotix | Date: 2010-07-09

The present application relates to activable nanoparticles which can be used in the health sector, in particular in human health, to disturb, alter or destroy target cells, tissues or organs. It more particularly relates to nanoparticles which can generate a significantly efficient therapeutic effect, when exposed to ionizing radiations. The inventive nanoparticle is a metallic nanoparticle having, as the largest size, a size comprised between about 80 and 105 nm, the metal having preferably an atomic number (Z) of at least 25. The invention also relates to pharmaceutical compositions comprising a population of nanoparticles as defined previously, as well as to their uses.


Grant
Agency: Cordis | Branch: H2020 | Program: CSA | Phase: NMP-09-2014 | Award Amount: 2.00M | Year: 2015

ENATRANS main objective is to network and support SMEs in translation of nanomedicine in Europe by providing a one-stop-shop service to interact and share information, experience and advice with up-to-date information and interactive tools, but also enabling personal contacts. To be successful SMEs need to understand the requirements of the complex ecosystem made up of regulatory and reimbursement agencies, as well as the requirements of large industrial companies and clinical needs. ENATRANS will gather and provide information about approval processes, regulatory authorities and agencies, clinical and market data, and specific nanomedicine value chain analysis, relevant SME support projects and organisations. ENATRANS will convert this critical information in dedicated learning programs and tools dedicated to translation of nanomedicine. ENATRANS aims at implementing the concept of a Translation Advisory Board (TAB) as central element of the ETPN White Paper. A TAB will be set-up with senior experienced translation experts to guide R&D teams (in SMEs and research institutes) along the translation process to successfully make it to clinical trials and later to the market. Promising projects identified and supported by the TAB need access to clinical centers for first studies in patients, which are able to handle the specificity of new nanotechnology based therapeutics. In addition, financial resources are needed to go pass the regulatory and scale-up processes, which often require funding from investors and/or large companies. ENATRANS will build bridges to clinical trial centers, investors and large companies. Promising projects need guidance to successfully master privileged contacts with the medical, the business or the investment community. ENATRANS will deliver special coaching sessions prior to showcasing of promising projects. Partners in ENATRANS are VDI/VDE-IT, Nanobiotix, CEA, bioanalytik-muenster, Tel Aviv University, Fondazione Don Gnocchi, TecMinho.


The present invention relates to novel nanoparticles which can be advantageously used in the health sector as diagnostic and/or therapeutic agents. Nanoparticles of the invention comprise a metallic material at least partly covered with an hafnium oxide material or embedded therein. When compared to existing products, these nanoparticles offer a remarkable benefit over risk ratio. Specifically, these nanoparticles potentiate the efficiency of known metallic nanoparticles. Indeed, they retain the metal intrinsic properties and are now in addition safely usable in a mammal, in particular in a human being. The invention also relates to methods for producing said nanoparticles, to compositions containing same, and to uses thereof.

Discover hidden collaborations